Inhibitory interactions of Aspalathus linearis (rooibos) extracts and compounds, aspalathin and Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid, on cytochromes metabolizing hypoglycemic and hypolipidemic drugs

Molecules

Volumn 21, Issue 11, 2016, Pages

  Patel, Oelfah ^a,d   Muller, Christo ^a   Joubert, Elizabeth ^b,c   Louw, Johan ^a   Rosenkranz, Bernd ^d   Awortwe, Charles ^a,d  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b ARC INFRUITEC NIETVOORBIJ   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Aspalathin; CYP2C8; CYP2C9 and CYP3A4; Herb drug interaction; Rooibos; Z 2 ( D glucopyranosyloxy) 3 phenylpropenoic acid

Indexed keywords

3-PHENYLPROPIONIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ASPALATHIN; CHALCONE DERIVATIVE; CYTOCHROME P450; PHENYLPROPIONIC ACID DERIVATIVE; PLANT EXTRACT;

ASPALATHUS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HERB DRUG INTERACTION; METABOLISM;

ASPALATHUS; CHALCONES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HERB-DRUG INTERACTIONS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; PHENYLPROPIONATES; PLANT EXTRACTS;

EID: 84997497931     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21111515     Document Type: Article

References (61)

1. Joubert, E.; de Beer, D. Rooibos (Aspalathus linearis) beyond the farm gate: From herbal tea to potential phytopharmaceutical. S. Afr. J. Bot. 2011, 77, 869-886.
2. Baba, H.; Ohtsuka, Y.; Haruna, H.; Lee, T.; Nagata, S.; Maeda, M.; Yamashiro, Y.; Shimizu, T. Studies of anti-inflammatory effects of Rooibos tea in rats. Pediatr. Int. 2009, 51, 700-704.
3. Marnewick, J.L.; Gelderblom, W.C.; Joubert, E. An investigation on the antimutagenic properties of South African herbal teas. Mutat. Res. 2000, 471, 157-166.
4. Marnewick, J.; Joubert, E.; Joseph, S.; Swanevelder, S.; Swart, P.; Gelderblom, W. Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas. Cancer Lett. 2005, 224, 193-202.
5. Marnewick, J.L.; van der Westhuizen, F.H.; Joubert, E.; Swanevelder, S.; Swart, P.; Gelderblom, W.C. Chemoprotective properties of rooibos (Aspalathus linearis), honeybush (Cyclopia intermedia) herbal and green and black (Camellia sinensis) teas against cancer promotion induced by fumonisin B1 in rat liver. Food Chem. Toxicol. 2009, 47, 220-229.
6. Sissing, L.; Marnewick, J.; de Kock, M.; Swanevelder, S.; Joubert, E.; Gelderblom, W. Modulating effects of rooibos and honeybush herbal teas on the development of esophageal papillomas in rats. Nutr. Cancer 2011, 63, 600-610.
7. Beltran-Debon, R.; Rull, A.; Rodriguez-Sanabria, F.; Iswaldi, I.; Herranz-Lopez, M.; Aragones, G.; Camps, J.; Alonso-Villaverde, C.; Menendez, J.A.; Micol, V.; et al. Continuous administration of polyphenols from aqueous rooibos (Aspalathus linearis) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. Phytomedicine 2011, 18, 414-424.
8. Mazibuko, S.E.; Muller, C.J.; Joubert, E.; de Beer, D.; Johnson, R.; Opoku, A.R.; Louw, J. Amelioration of palmitate-induced insulin resistance in C2C12 muscle cells by rooibos (Aspalathus linearis). Phytomedicine 2013, 20, 813-819.
9. Muller, C.J.; Joubert, E.; de Beer, D.; Sanderson, M.; Malherbe, C.J.; Fey, S.J.; Louw, J. Acute assessment of an aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential. Phytomedicine 2012, 20, 32-39.
10. Kamakura, R.; Son, M.J.; de Beer, D.; Joubert, E.; Miura, Y.; Yagasaki, K. Antidiabetic effect of green rooibos (Aspalathus linearis) extract in cultured cells and type 2 diabetic model KK-A(y) mice. Cytotechnology 2015, 67, 699-710.
11. Sanderson, M.; Mazibuko, S.E.; Joubert, E.; de Beer, D.; Johnson, R.; Pheiffer, C.; Louw, J.; Muller, C.J. Effects of fermented rooibos (Aspalathus linearis) on adipocyte differentiation. Phytomedicine 2014, 21, 109-117.
12. Marnewick, J.L.; Rautenbach, F.; Venter, I.; Neethling, H.; Blackhurst, D.M.; Wolmarans, P.; Macharia, M. Effects of rooibos (Aspalathus linearis) on oxidative stress and biochemical parameters in adults at risk for cardiovascular disease. J. Ethnopharmacol. 2011, 133, 46-52.
13. Pantsi, W.G.; Marnewick, J.L.; Esterhuyse, A.J.; Rautenbach, F.; van Rooyen, J. Rooibos (Aspalathus linearis) offers cardiac protection against ischaemia/reperfusion in the isolated perfused rat heart. Phytomedicine 2011, 18, 1220-1228.
14. Dludla, P.V.; Muller, C.J.; Louw, J.; Joubert, E.; Salie, R.; Opoku, A.R.; Johnson, R. The cardioprotective effect of an aqueous extract of fermented rooibos (Aspalathus linearis) on cultured cardiomyocytes derived from diabetic rats. Phytomedicine 2014, 21, 595-601.
15. Hu, F.B. Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care 2011, 34, 1249-1257.
16. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
17. Hossain, P.; Kawar, B.; El Nahas, M. Obesity and diabetes in the developing world - A growing challenge. N. Engl. J. Med. 2007, 356, 213-215.
18. Kawano, A.; Nakamura, H.; Hata, S.; Minakawa, M.; Miura, Y.; Yagasaki, K. Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009, 16, 437-443.
19. Son, M.J.; Minakawa, M.; Miura, Y.; Yagasaki, K. Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur. J. Nutr. 2013, 52, 1607-1619.
20. Johnson, R.; Dludla, P.; Joubert, E.; February, F.; Mazibuko, S.; Ghoor, S.; Muller, C.; Louw, J. Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose-induced shifts in substrate preference and apoptosis. Mol. Nutr. Food. Res. 2016, 60, 922-934.
21. Ku, S.K.; Kwak, S.; Kim, Y.; Bae, J.S. Aspalathin and nothofagin from rooibos (Aspalathus linearis) inhibits high glucose-induced inflammation in vitro and in vivo. Inflammation 2015, 38, 445-455.
22. Muller, C.J.; Joubert, E.; Pheiffer, C.; Ghoor, S.; Sanderson, M.; Chellan, N.; Fey, S.J.; Louw, J. Z-2-(β-Dglucopyranosyloxy)-3-phenylpropenoic acid, an alpha-hydroxy acid from rooibos (Aspalathus linearis) with hypoglycemic activity. Mol. Nutr. Food Res. 2013, 57, 2216-2222.
23. Himpe, E.; Cunha, D.A.; Song, I.; Bugliani, M.; Marchetti, P.; Cnop, M.; Bouwens, L. Phenylpropenoic acid glucoside from rooibos protects pancreatic beta cells against cell death induced by acute injury. PLoS ONE 2016, 11, 11.
24. Mathijs, I.; da Cunha, D.A.; Himpe, E.; Ladriere, L.; Chellan, N.; Roux, C.R.; Joubert, E.; Muller, C.; Cnop, M.; Louw, J.; et al. Phenylpropenoic acid glucoside augments pancreatic beta cell mass in high-fat diet-fed mice and protects beta cells from ER stress-induced apoptosis. Mol. Nutr. Food Res. 2014, 58, 1980-1990.
25. Dludla, P.V.; Muller, C.J.; Joubert, E.; Louw, J.; Gabuza, K.B.; Huisamen, B.; Essop, M.F.; Johnson, R. Phenylpyruvic acid-2-O-β-D-glucoside attenuates high glucose-induced apoptosis in H9c2 cardiomyocytes. Planta Med. 2016.
26. Van Andel, T.; Carvalheiro, L.G. Why urban citizens in developing countries use traditional medicines: The case of suriname. J. Evid. Based Complement. Altern. Med. 2013, 2013, 687197.
27. Bodeker, G.; Kronenberg, F. A public health agenda for traditional, complementary, and alternative medicine. Am. J. Public Health 2002, 92, 1582-1591.
28. Kong, W.M.; Chik, Z.; Ramachandra, M.; Subramaniam, U.; Aziddin, R.E.; Mohamed, Z. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules 2011, 16, 7344-7356.
29. Cupp, M.J.; Tracy, T.S. Cytochrome P450: New nomenclature and clinical implications. Am. Fam. Phys. 1998, 57, 107-116.
30. Ogu, C.C.; Maxa, J.L. Drug interactions due to cytochrome P450. Proceedings (Bayl. Univ. Med. Cent.) 2000, 13, 421-423.
31. Basheer, L.; Kerem, Z. Interactions between CYP3A4 and dietary polyphenols. Oxid. Med. Cell. Longev. 2015, 2015, 854015.
32. Liu, M.Z.; Zhang, Y.L.; Zeng, M.Z.; He, F.Z.; Luo, Z.Y.; Luo, J.Q.; Wen, J.G.; Chen, X.P.; Zhou, H.H.; Zhang, W. Pharmacogenomics and herb-drug interactions: Merge of future and tradition. J. Evid. Based Complement. Altern. Med. 2015, 2015, 321091.
33. Hermann, R.; von Richter, O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012, 78, 1458-1477.
34. Bushra, R.; Aslam, N.; Khan, A.Y. Food-drug interactions. Oman Med. J. 2011, 26, 77-83.
35. Hussain, M.S. Patient counseling about herbal-drug interactions. Afr. J. Tradit. Complement. Altern. Med. 2011, 8, 152-163.
36. Tachjian, A.; Maria, V.; Jahangir, A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J. Am. Coll. Cardiol. 2010, 55, 515-525.
37. Fasinu, P.S.; Bouic, P.J.; Rosenkranz, B. An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol. 2012, 3, 69.
38. Fasinu, P.S.; Bouic, P.J.; Rosenkranz, B. The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction. Afr. J. Tradit. Complement. Altern. Med. 2014, 11, 54-61.
39. Hansen, T.S.; Nilsen, O.G. In vitro CYP3A4 metabolism: Inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin. Pharmacol. Toxicol. 2008, 103, 445-449.
40. Hutzler, J.M.; Cook, J.; Fleishaker, J.C. Drug-drug interactions: Designing development programs and appropriate product labeling. Pharmacokinet. Drug Dev. 2011, 21-56.
41. Bell, L.; Bickford, S.; Nguyen, P.H.;Wang, J.; He, T.; Zhang, B.; Friche, Y.; Zimmerlin, A.; Urban, L.; Bojanic, D. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J. Biomol. Screen. 2008, 13, 343-353.
42. Kimura, Y.; Ito, H.; Ohnishi, R.; Hatano, T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem. Toxicol. 2010, 48, 429-435.
43. Yamaori, S.; Ebisawa, J.; Okushima, Y.; Yamamoto, I.;Watanabe, K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011, 88, 730-736.
44. Pan, Y.; Tiong, K.H.; Abd-Rashid, B.A.; Ismail, Z.; Ismail, R.; Mak, J.W.; Ong, C.E. Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts. J. Ethnopharmacol. 2012, 143, 586-591.
45. Matsuda, K.; Nishimura, Y.; Kurata, N.; Iwase, M.; Yasuhara, H. Effects of continuous ingestion of herbal teas on intestinal CYP3A in the rat. J. Pharmacol. Sci. 2007, 103, 214-221.
46. Quintieri, L.; Palatini, P.; Nassi, A.; Ruzza, P.; Floreani, M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem. Pharmacol. 2008, 75, 1426-1437.
47. Patel, J.; Buddha, B.; Dey, S.; Pal, D.; Mitra, A.K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: Changes in P-gp and CYP3A4 activity. Am. J. Ther. 2004, 11, 262-277.
48. Yu, C.P.; Wu, P.P.; Hou, Y.C.; Lin, S.P.; Tsai, S.Y.; Chen, C.T.; Chao, P.D. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J. Agric. Food Chem. 2011, 59, 4644-4648.
49. Raucy, J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 2003, 31, 533-539.
50. Vijayakumar, T.M.; Kumar, R.M.; Agrawal, A.; Dubey, G.P.; Ilango, K. Comparative inhibitory potential of selected dietary bioactive polyphenols, phytosterols on CYP3A4 and CYP2D6 with fluorometric high-throughput screening. J. Food Sci. Technol. 2015, 52, 4537-4543.
51. Belpaire, F.M.; Bogaert, M.G. Cytochrome P450: Genetic polymorphism and drug interactions. Acta Clin. Belg. 1996, 51, 254-260.
52. Ali, Z.K.; Kim, R.J.; Ysla, F.M. CYP2C9 polymorphisms: Considerations in NSAID therapy. Curr. Opin. Drug Discov. Dev. 2009, 12, 108-114.
53. Lee, C.R.; Goldstein, J.A.; Pieper, J.A. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data. Pharmacogenetics 2002, 12, 251-263.
54. Wanwimolruk, S.; Phopin, K.; Prachayasittikul, V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). EXCLI J. 2014, 13, 869-896.
55. Van Booven, D.; Marsh, S.; McLeod, H.; Carrillo, M.W.; Sangkuhl, K.; Klein, T.E.; Altman, R.B. Cytochrome P450 2C9-CYP2C9. Pharmacogenet. Genom. 2010, 20, 277-281.
56. Pirmohamed, M.; Park, B.K. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003, 192, 23-32.
57. Huang, S.M.; Temple, R.; Throckmorton, D.; Lesko, L. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 2007, 81, 298-304.
58. Tirkkonen, T.; Heikkila, P.; Huupponen, R.; Laine, K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J. Intern. Med. 2010, 268, 359-366.
59. Tornio, A.; Niemi, M.; Neuvonen, P.J.; Backman, J.T. Drug interactions with oral antidiabetic agents: Pharmacokinetic mechanisms and clinical implications. Trends Pharmacol. Sci. 2012, 33, 312-322.
60. Ho, P.C.; Saville, D.J.; Wanwimolruk, S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci. 2001, 4, 217-227.
61. Beelders, T.; Sigge, G.O.; Joubert, E.; de Beer, D.; de Villiers, A. Kinetic optimisation of the reversed phase liquid chromatographic separation of rooibos tea (Aspalathus linearis) phenolics on conventional high performance liquid chromatographic instrumentation. J. Chromatogr. A 2012, 1219, 128-139.